Type of publication:
Conference abstract
Author(s):
*Jones, G.
Citation:
Colorectal Disease. Conference: Association of Coloproctology of Great Britain and Ireland Annual Meeting. Edinburgh United Kingdom. 24(Supplement 2) (pp 58), 2022. Date of Publication: September 2022.
Abstract:
Background: Faecal calprotectin testing is recommended by the National Institute for Health and Care Excellence (NICE) to distinguish between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) after cancer exclusion. Many patients do not produce faecal samples as requested and therefore a direct collection technique may have a role in IBD diagnosis or monitoring. We compared the performance of faecal and rectal mucus calprotectin collected with the OriColTM sampling device Methods: Sixty-six patients with confirmed or suspected IBD were recruited in the Oricol-EGI- 01 Study. OriColTM and matched stool samples were collected and processed following standard operating procedures. Calprotectin concentrations were measured using IDK Calprotectin and fCAL assays Results: Calprotectin was detectable in the OriColTM samples with good discrimination across the calprotectin assays and discernible correlation to corresponding faecal calprotectin concentrations Using thresholds determined for rectal mucus calprotectin (calculated by linear regression), the percentage agreement between calprotectin concentrations in stool and rectal mucus for patients with faecal calprotectin >=50 mug/g was between 68% and 91% with a percentage agreement at <50 mug/g between 40% and 71% with IDK Calprotectin and fCAL assays respectively. Good agreement was observed for IBD patients with the results being above the threshold for both faecal and rectal mucus calprotectin with 93% and 86% for IDK Calprotectin and fCAL assays respectively Conclusion(s): The OriColTM Calprotectin Kit was successfully used to collect rectal mucus and measure calprotectin concentrations with positive correlation to corresponding faecal calprotectin and is potentially a new and acceptable modality in IBD patients.
Link to full-text [p. 37, NHS OpenAthens account required]